DK0792292T3 - Orphan-receptor - Google Patents

Orphan-receptor

Info

Publication number
DK0792292T3
DK0792292T3 DK96931047T DK96931047T DK0792292T3 DK 0792292 T3 DK0792292 T3 DK 0792292T3 DK 96931047 T DK96931047 T DK 96931047T DK 96931047 T DK96931047 T DK 96931047T DK 0792292 T3 DK0792292 T3 DK 0792292T3
Authority
DK
Denmark
Prior art keywords
amino acid
acid sequence
receptor
relates
disorders
Prior art date
Application number
DK96931047T
Other languages
English (en)
Other versions
DK0792292T4 (da
Inventor
George G J Kuiper
Eva Enmark
Jan-Ake Gustafsson
Original Assignee
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0792292(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9518272.1A external-priority patent/GB9518272D0/en
Priority claimed from GBGB9605550.4A external-priority patent/GB9605550D0/en
Priority claimed from GBGB9607532.0A external-priority patent/GB9607532D0/en
Priority claimed from GBGB9609576.5A external-priority patent/GB9609576D0/en
Application filed by Karobio Ab filed Critical Karobio Ab
Application granted granted Critical
Publication of DK0792292T3 publication Critical patent/DK0792292T3/da
Publication of DK0792292T4 publication Critical patent/DK0792292T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK96931047T 1995-09-08 1996-09-09 Orphan-receptor DK0792292T4 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9518272.1A GB9518272D0 (en) 1995-09-08 1995-09-08 Orphan receptor
GBGB9605550.4A GB9605550D0 (en) 1996-03-15 1996-03-15 Orphan receptor
GBGB9607532.0A GB9607532D0 (en) 1996-04-11 1996-04-11 Orphan receptor
GBGB9609576.5A GB9609576D0 (en) 1996-05-08 1996-05-08 Orphan receptor
PCT/EP1996/003933 WO1997009348A2 (en) 1995-09-08 1996-09-09 Orphan receptor

Publications (2)

Publication Number Publication Date
DK0792292T3 true DK0792292T3 (da) 2000-02-07
DK0792292T4 DK0792292T4 (da) 2009-07-20

Family

ID=27451339

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96931047T DK0792292T4 (da) 1995-09-08 1996-09-09 Orphan-receptor

Country Status (12)

Country Link
US (2) US5958710A (da)
EP (2) EP0792292B2 (da)
JP (4) JP3131649B2 (da)
KR (1) KR100263137B1 (da)
AT (1) ATE183516T1 (da)
AU (1) AU715528B2 (da)
CA (1) CA2201098C (da)
DE (2) DE69603827T3 (da)
DK (1) DK0792292T4 (da)
ES (1) ES2135249T5 (da)
GR (2) GR980300029T1 (da)
WO (1) WO1997009348A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
EP0866127A3 (en) * 1997-03-17 1999-12-22 Smithkline Beecham Plc HE8AN36, a steroid hormone receptor homolog
EP0980386A2 (en) * 1997-06-10 2000-02-23 Karo Bio Ab Estrogen receptor crystals and ligands
US7157568B1 (en) 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
ES2268789T3 (es) * 1997-09-08 2007-03-16 MERCK & CO., INC. Receptor de estrogeno.
GB9814620D0 (en) * 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
DE19839115A1 (de) * 1998-08-27 2000-03-09 Ihf Inst Fuer Hormon Und Fortp Klonierung und Expression von Rinder Estrogenrezeptor-beta
EP1400810A3 (en) * 1999-04-09 2005-03-02 Karo Bio Ab Estrogen receptors and bone disease
AU4546900A (en) * 1999-04-09 2000-11-14 Karo Bio Ab Estrogen receptors and bone
AU2002247702A1 (en) * 2001-02-09 2002-08-28 Lion Bioscience Ag Novel cofactors of the estrogen receptor beta and methods of use
WO2002070697A1 (en) * 2001-03-02 2002-09-12 Lion Bioscience Ag Mammalian nuclear receptor l67 and methods of use
CA2448235A1 (en) 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
JP4381810B2 (ja) 2001-11-19 2009-12-09 イーライ リリー アンド カンパニー 選択的エストロゲン受容体βアゴニストとしての置換ベンゾピラン
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AU2002353076A1 (en) * 2001-12-07 2003-06-23 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor beta expression
CA2365811A1 (en) * 2001-12-21 2003-06-21 Institut De Cardiologie A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
KR101092349B1 (ko) 2003-02-21 2011-12-09 다우 글로벌 테크놀로지스 엘엘씨 공액 올레핀의 단독중합법 또는 공중합법
DE602004016150D1 (de) 2003-04-21 2008-10-09 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
ES2338119T3 (es) 2003-04-21 2010-05-04 Eli Lilly And Company Benzopiranos sustituidos como agonistas selectivos del receptor-beta de estrogeno.
EP1667955A2 (en) 2003-07-28 2006-06-14 SmithKline Beecham Corporation Cycloalkylidene compounds as modulators of the estrogen receptor
EP1709443A2 (en) * 2003-12-18 2006-10-11 Procognia, Ltd. Method for analyzing a glycomolecule
JP2008512458A (ja) 2004-09-07 2008-04-24 ワイス ６Ｈ−［１］ベンゾピラノ［４，３−ｂ］キノリン及びエストロゲン様物質としてのそれらの使用
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5262300A (en) * 1988-11-30 1993-11-16 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5602009A (en) * 1988-12-23 1997-02-11 The Salk Institute For Biological Studies Dominant negative chimeras of the steroid/thyroid superfamily of receptors
JPH04505012A (ja) * 1989-03-17 1992-09-03 ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ ホルモン応答要素組成物およびアッセイ
US5438126A (en) * 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
WO1995013373A1 (en) * 1993-11-10 1995-05-18 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor

Also Published As

Publication number Publication date
CA2201098A1 (en) 1997-03-13
ES2135249T3 (es) 1999-10-16
US20030113803A1 (en) 2003-06-19
AU715528B2 (en) 2000-02-03
US5958710A (en) 1999-09-28
DK0792292T4 (da) 2009-07-20
CA2201098C (en) 2001-03-27
EP0792292A2 (en) 1997-09-03
WO1997009348A2 (en) 1997-03-13
GR3031618T3 (en) 2000-01-31
DE69603827D1 (de) 1999-09-23
DE792292T1 (de) 1998-09-03
ES2135249T5 (es) 2009-09-10
ATE183516T1 (de) 1999-09-15
AU6988096A (en) 1997-03-27
EP0792292B2 (en) 2009-04-15
WO1997009348A3 (en) 1997-04-24
JP2002010788A (ja) 2002-01-15
EP0935000A2 (en) 1999-08-11
JP2005204667A (ja) 2005-08-04
EP0792292B1 (en) 1999-08-18
DE69603827T3 (de) 2009-11-05
US7132261B2 (en) 2006-11-07
KR100263137B1 (ko) 2000-08-01
DE69603827T2 (de) 2000-02-24
JP3131649B2 (ja) 2001-02-05
EP0935000A3 (en) 1999-09-08
GR980300029T1 (en) 1998-04-30
JPH11502417A (ja) 1999-03-02
JP2005204666A (ja) 2005-08-04

Similar Documents

Publication Publication Date Title
DK0792292T4 (da) Orphan-receptor
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
PT773962E (pt) Anticorpos que activam um receptor da eritropoietina
ES2151277T3 (es) Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
BR9710636A (pt) Análogo de somatostatina ciclizada da espinha dorsal, uso do mesmo, composição farmacêutica,e , processo de tratamento de distúrbios endócrinos, neoplasmas ou distúrbios metabólicos.
MXPA00012586A (es) Glicosulfopeptidos y metodos de sintesis y uso de los mismos.
BR9712589A (pt) Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica.
AU6045398A (en) Androgen synthesis inhibitors
NO961706L (no) Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
BR9811264A (pt) Composições imunogênicas ao receptor de gastrina/cck-b e métodos para o tratamento de tumores
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
DE60045751D1 (de) Therapeutische Behandlung androgenrezeptorbedingter Leiden
PL328858A1 (en) Immunogenous peptides
MX9708401A (es) Genes reguladores de la cromatina.
DK279790A (da) Aromatiske steroid-5-alfa-reduktaseinhibitorer
UA66861C2 (uk) 2-феніл-1-[4-(2-аміноетокси)бензил]індол в комбінації з естрогенами, способи лікування та продукт для лікування
DK0741756T3 (da) Dendritisk makromolekyle og fremgangsmåde til fremstilling heraf
LEVI-MONTALCINI et al. Hormonal control of the NGF content in the submaxillary glands of mice
Banerjee et al. Distinct colchicine binding kinetics of bovine brain tubulin lacking the type III isotype of beta-tubulin
ATE237334T1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
BR0110208A (pt) Composições e terapias para distúrbios associados com hiperlipidemia
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods